Delia A. Deschaine, Member of the Firm in the Health Care & Life Sciences practice, in the firm’s Washington, DC, office, was featured in Law360, in “Health Hires,” by Kevin Stawicki. (Read the full version – subscription required.)
Following is an excerpt:
Delia A. Deschaine has joined Epstein Becker Green’s health care and life sciences practice in Washington, D.C., after spending nearly six years at Hogan Lovells.
Deschaine, who advises pharmaceutical and biotechnology companies on regulatory matters involving the Federal Food, Drug and Cosmetic Act and the Controlled Substances Act, joined the firm earlier this week.
“I am thrilled to be joining the talented team at EBG and look forward to being a part of the focused platform that the firm offers,” Deschaine said in a statement on June 1. “The health care and life sciences industries face tremendous opportunities and challenges, and I cannot wait to bring all of my experience to the table to serve the firm’s outstanding clients.”
The firm said she has handled a variety of compliance matters involving the U.S. Food and Drug Administration and U.S. Drug Enforcement Administration.
“The global pandemic has created opportunities for health care and life sciences companies to innovate; however, with that comes heightened regulatory obligations and potential scrutiny from enforcement agencies,” George Breen, chair of the firm’s national health care and life sciences practice steering committee, said in the statement. “Delia brings to us sought-after experience representing pharmaceutical, medical device and biotechnology companies in FDA and DEA enforcement actions and litigation.”
Earlier in her career, Deschaine worked at Hyman Phelps & McNamara PC for two years and had a one year stint as an attorney adviser for the U.S. Department of Justice, Drug Enforcement Agency. She earned her law degree from the University of Maryland School of Law.
